Related Tags >> infectious diseases FDA antibiotic Phase III

MRSA News

Most Popular MRSA Story

FDA to review Theravance's telavancin response

March 6, 2008 — 6:59am ET

More news in Theravance's ongoing battle to win approval for its antibiotic telavancin: the FDA has accepted the company's response to the Read more...

MRSA Press Releases

Usage of Zyvox Has Flattened or Declined in the Major European Markets While Uptake of Cubicin and Tygacil Has Climbed Yea
Fujifilm Diosynth Biotechnologies and ContraFect Corporation Announce Development and Manufacturing Collaboration for Nove
Roche Diagnostics Supports Fight Against MRSA as a Sponsor of Annual World MRSA Day on October 1
PURE Bioscience Presents PURE Hard Surface at American Correctional Association’s Annual Congress
Excelimmune Completes $10.5 Million Series B Financing

Latest Headlines

MRSA research lags far behind AIDS in NIH support
July 5, 2011
Biotechs pick up slack in antibiotics development
May 17, 2011
Drug-resistant superbug highlights need for new antibiotics
August 12, 2010
FDA: Targanta must conduct new oritavancin study
December 9, 2008
Basilea shares plunge on antibiotic delay
March 18, 2008
Cepheid cashes in on MRSA trends--for now
March 7, 2008
FDA to review Theravance's telavancin response
March 6, 2008
FDA cancels meeting as hopes rise for Basilea
February 13, 2008
ALSO NOTED: Ventana and Roche forge confidentiality agreement; Rigel wins $3M payment; and much more...
November 14, 2007
Dry antibiotic pipeline concerns infectious disease experts
November 5, 2007
Basilea reports positive Phase III antibiotic data
October 9, 2007
WHO: Infectious disease a growing threat
August 24, 2007

Paid Research Reports

More Research Reports >>